Biomay’s Cas9 mRNA portfolio includes multiple optimized formats—featuring distinct 5′ cap analogs, 3′ poly(A) tail lengths and various nucleoside modifications. These variants are engineered to meet the specific needs of genome editing applications, including T-cell receptor modification (TCR-T) and chimeric antigen receptor (CAR-T) cell engineering.
Biomay’s Cas9 mRNA is produced using a fully integrated GMP manufacturing platform supported by a panel of qualified analytical assays. Functional performance has been confirmed in cell-based assays, demonstrating equivalence to leading benchmark Cas9 mRNA products. A high purity, a high capping effciency (more than 95%) and a low double-stranded RNA (dsRNA) content are essential features of the product.
As an FDA-inspected manufacturer, Biomay is committed to delivering mRNA products of the highest quality standards, thereby empowering clients from early research to clinical-stage programs. With this launch, Biomay further strengthens its position as a one-stop provider for genome editing tools. Whether for early-stage research or clinical programs, Biomay’s Cas9 mRNA provides reliability, quality, and speed — all from a single trusted source.About Biomay
Biomay AG is a privately owned and fully integrated Contract Development and Manufacturing Organization (CDMO) based in Vienna, Austria. Founded in 1984, the expression of recombinant proteins by utilizing E. coli has been Biomay´s business focus from the very beginning. Today, Biomay offers cGMP services for manufacturing of therapeutic proteins, plasmid DNA (pDNA) and messenger RNA (mRNA). The company´s scope of CDMO services comprises process and analytical development, cell banking, cGMP manufacturing of drug substance and aseptic filling of drug product.
About Biomay
Biomay is a fully integrated Contract Development and Manufacturing Organization (CDMO) based in Vienna, Austria. Founded in 1984, the expression of recombinant proteins in E. coli has been Biomay’s business focus yet from its beginning. Today, Biomay offers cGMP services for manufacturing of messenger RNA (mRNA), circular plasmid DNA, linear IVT-template DNA and therapeutic recombinant proteins.
Biomay operates a dedicated mRNA Competence Center for cGMP manufacturing and QC testing of mRNA drug substance and drug product (clinical, commercial). The company’s scope of services comprises process and analytical development, cell banking, R&D material supply, cGMP manufacturing, lipid nanoparticle (LNP) formulation and aseptic filling. Biomay’s facilities are inspected by the US FDA.
Contact:
Dr. Angela Neubauer, SVP Client Business; request(at)biomay.com
Biomay AG, Ada Lovelace-Str. 2, A-1220 Vienna, Austria; www.biomay.com